Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Medical Oncology · Hereditary Breast and Ovarian Cancer Syndrome

Which Specialists Treat Hereditary Breast & Ovarian Cancer?

At a Glance

Because Hereditary Breast and Ovarian Cancer (HBOC) syndrome affects multiple organs, it cannot be managed by a single doctor. Patients need a coordinated team of genetic counselors, oncologists, and specialized surgeons to handle personalized cancer screenings and risk-reducing treatments.

In this answer

3 sections

01

The Core Medical Team

02

Additional Specialists and Ongoing Care

03

The Value of High-Risk Clinics

If you have been diagnosed with a mutation linked to Hereditary Breast and Ovarian Cancer (HBOC) syndrome, such as a BRCA1 or BRCA2 mutation, you will need a team of different specialists to manage your health. Because HBOC affects multiple organs in both men and women, and involves complex decisions about screening and surgery, no single doctor can manage it alone. Your core team may include genetic counselors, oncologists, various surgeons, and mental health professionals [1][2].

The Core Medical Team

Genetic Counselors

A genetic counselor is often your first point of contact. They help you understand your specific genetic test results, explain exactly how your mutation impacts your cancer risk, and discuss what this means for your family members [3]. They provide personalized coaching to help you weigh your options [4] and can coordinate cascade testing—the process of testing your parents, siblings, and children to see if they share the mutation [5][6].

Medical Oncologists

Even if you do not have cancer, a medical oncologist plays a vital role in your preventive care. It can be unsettling to sit in an oncology waiting room when you do not have cancer, but these specialists are experts in medical risk management. They can discuss whether medications to lower cancer risk (chemoprevention) are right for you, help coordinate your long-term surveillance plan, and connect you with clinical registries or trials [7][4].

Breast Surgeons

A specialist breast surgeon or surgical oncologist will monitor your breast health. For women, they help you decide if and when to have a risk-reducing mastectomy (surgery to remove healthy breast tissue to prevent cancer) [8][9]. Because men with HBOC mutations also face an elevated risk of male breast cancer, they may see a breast specialist for clinical exams or to evaluate any physical changes.

Gynecologic Oncologists (For Women)

Because ovarian cancer is difficult to screen for, a gynecologic oncologist is essential for managing female pelvic health. They specialize in cancers of the reproductive system and will discuss risk-reducing salpingo-oophorectomy (RRSO), which is the surgical removal of the ovaries and fallopian tubes [9][10]. They can also help manage the symptoms of sudden surgical menopause that occur if your ovaries are removed before natural menopause.

Urologists (For Men)

Men with HBOC mutations, particularly BRCA2, have a significantly higher risk of developing aggressive prostate cancer [11]. A urologist will oversee your prostate screening, typically starting at an earlier age (often 40), using PSA blood tests and physical exams to monitor your prostate health.

Plastic and Reconstructive Surgeons

If you choose to undergo a preventive mastectomy, a plastic surgeon will work closely with your breast surgeon to rebuild the shape of your breasts [12][13]. They will explain the different types of reconstruction—such as using implants or your own tissue (autologous reconstruction)—and discuss what to expect regarding recovery, cosmetic outcomes, and potential complications [14][15]. Often, breast removal and reconstruction can be done in a single operation to reduce your overall surgical burden [12].

Additional Specialists and Ongoing Care

Your routine Primary Care Provider (PCP) does not disappear; they continue to manage your general health and can help initiate referrals to these specialists. Depending on your specific mutation and family history, your extended team may also include:

  • Psychologists or Therapists: A BRCA diagnosis and the prospect of preventive surgeries can be overwhelming. Mental health professionals who understand cancer worry are crucial for supporting your emotional well-being [16].
  • Radiologists: Breast imaging specialists who interpret your annual MRIs and mammograms, playing a crucial role in catching any potential cancers early [17][18].
  • Dermatologists: BRCA2 mutations in particular are linked to an elevated risk of melanoma, making annual full-body skin checks an important part of your routine [19][20].
  • Gastroenterologists: If your mutation and family history put you at higher risk for pancreatic cancer, these specialists can perform advanced screening like endoscopic ultrasounds (EUS) or coordinate specialized MRIs [21][22].

The Value of High-Risk Clinics

Managing HBOC requires intense coordination. Trying to schedule multiple screenings, track test results, and communicate between half a dozen different independent doctors can be exhausting and stressful.

Because of this, many patients benefit from seeking care at a high-risk cancer clinic or a comprehensive cancer center. These centers offer centralized, team-based care where all your specialists work together under one roof [23].

The benefits of a specialized high-risk clinic include:

  • Coordinated Care: Your specialists regularly communicate with each other, ensuring that your surveillance plan stays on track without you having to act as the messenger [1].
  • Expertise in Rare Risks: Providers at these clinics see hundreds of patients with genetic mutations, meaning they are deeply familiar with the latest research and guidelines [23].
  • Support Services: High-risk clinics often have built-in support for the emotional and physical side effects of HBOC, including access to sexual health specialists who can help you navigate intimacy after risk-reducing surgeries [24][25].

Common questions in this guide

What kind of doctor should I see for a BRCA mutation or HBOC syndrome?
Managing an HBOC or BRCA mutation requires a multidisciplinary team of specialists rather than a single doctor. Your core care team will typically include a genetic counselor, a medical oncologist, and specialized breast or gynecologic surgeons to monitor and lower your cancer risks.
Do men with HBOC syndrome need to see specialists?
Yes, men with HBOC mutations face higher risks for aggressive prostate cancer, male breast cancer, and melanoma. A urologist should oversee early prostate screenings, and men may also need to see breast specialists or dermatologists for routine exams.
What is a high-risk cancer clinic?
A high-risk cancer clinic is a specialized center where providers from multiple medical disciplines work together to manage patients with elevated cancer risks. These clinics help coordinate your complex screening schedules and ensure your specialists communicate seamlessly.
Why do I need to see a genetic counselor for HBOC?
A genetic counselor helps you understand what your specific genetic test results mean for your health. They also provide personalized coaching on how to discuss these risks with your family members and coordinate genetic testing for your relatives.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do you regularly treat patients who have my specific genetic mutation, rather than just the general public?
  2. 2.Do you work as part of a formal high-risk clinic or multidisciplinary team, and how will my records be shared among my specialists?
  3. 3.If I need risk-reducing surgery, what specialists will be involved in the operating room?
  4. 4.Who on my care team will be responsible for tracking my secondary screening needs, such as pancreatic, prostate, or skin checks?
  5. 5.What resources do you have for managing the side effects of preventive care, such as surgical menopause or sexual health changes?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Does Ovary Removal Reduce BRCA Breast Cancer Risk?How Do PARP Inhibitors Work for BRCA-Mutated Cancers?Can Tamoxifen Lower Breast Cancer Risk in BRCA Carriers?How Much Does Mastectomy Reduce Breast Cancer Risk?How to Find an Expert in Hereditary Breast & Ovarian CancerHow Do I Prepare a Family Cancer History for Genetics?Is HRT Safe After Ovary Removal for BRCA Carriers?What is the Difference Between BRCA1 and BRCA2 Mutations?Do I Meet the NCCN Criteria for BRCA Genetic Testing?What Causes PARP Inhibitor Resistance in BRCA Cancers?What is a VUS (Variant of Uncertain Significance) in BRCA?What is Cascade Testing for BRCA and HBOC Mutations?What Is the Male Breast Cancer Risk for BRCA Carriers?What is the BRCA Mutation Rate in Ashkenazi Jews?What Age Should BRCA Carriers Have Ovaries Removed?What Is My Pancreatic Cancer Risk with a BRCA Mutation?What Genes Besides BRCA Cause Breast & Ovarian Cancer?When Should BRCA Carriers Start Breast Cancer Screening?Why is Platinum Chemo Effective for BRCA Cancers?

References

References (25)
  1. 1

    Towards sustainable hereditary breast and ovarian cancer surveillance: insights from a single-center survey.

    Goto Y, Seki T, Nakato D, et al.

    Journal of human genetics 2026; doi:10.1038/s10038-026-01491-w.

    PMID: 42410220
  2. 2

    Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Daly MB, Pal T, Berry MP, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2021; (19(1)):77-102.

    PMID: 33406487
  3. 3

    Genetic testing for patients at risk of hereditary breast and ovarian cancer.

    DeTroye A, Gabbett K, Yi C, et al.

    JAAPA : official journal of the American Academy of Physician Assistants 2022; (35(10)):48-52 doi:10.1097/01.JAA.0000873796.81961.da.

    PMID: 36165549
  4. 4

    Breast cancer genetic mutation: Synthesis of women's experience.

    McNamara N, Feeney M, Giltenane M, Dowling M

    Journal of clinical nursing 2023; (32(13-14)):4144-4158 doi:10.1111/jocn.16498.

    PMID: 36016506
  5. 5

    Uptake of Cascade Genetic Testing for Hereditary Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis.

    Ahsan MD, Chandler IR, Min S, et al.

    Clinical obstetrics and gynecology 2024; (67(4)):702-710 doi:10.1097/GRF.0000000000000895.

    PMID: 39431491
  6. 6

    Double Heterozygosity for Germline Mutations in Chinese Breast Cancer Patients.

    Kwong A, Ho CYS, Au CH, Ma ESK

    Cancers 2024; (16(14)) doi:10.3390/cancers16142547.

    PMID: 39061189
  7. 7

    A case of hereditary breast and ovarian cancer syndrome of initially presented as cancer of unknown primary with lymph node metastases unveiled by genetic analysis.

    Yamada J, Fukuda K, Sugawara T, et al.

    International cancer conference journal 2024; (13(2)):139-143 doi:10.1007/s13691-023-00652-4.

    PMID: 38524651
  8. 8

    Risk-Reducing Mastectomy in BRCA1/2 and Other High-Risk Gene Carriers: Current Evidence and Practical Guidance.

    Lee JH, Ryu JM, Park JS, et al.

    Journal of breast cancer 2026; (29(1)):1-16 doi:10.4048/jbc.2025.0279.

    PMID: 41612657
  9. 9

    Ovarian cancer risk management in BRCA-mutation carriers: A comparison of six international and national guidelines.

    Matan LS, Perri T, Kogan L, et al.

    European journal of obstetrics, gynecology, and reproductive biology 2022; (278()):166-171 doi:10.1016/j.ejogrb.2022.09.035.

    PMID: 36208522
  10. 10

    Clinical and pathological outcomes of risk-reducing salpingo-oophorectomy for Japanese women with hereditary breast and ovarian cancer.

    Nomura H, Ikki A, Fusegi A, et al.

    International journal of clinical oncology 2021; (26(12)):2331-2337 doi:10.1007/s10147-021-02020-9.

    PMID: 34453642
  11. 11

    NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

    Daly MB, Pilarski R, Yurgelun MB, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(4)):380-391.

    PMID: 32259785
  12. 12

    Simultaneous Risk-Reducing Mastectomy and Salpingo-Oophorectomy in Patients with BRCA1 and BRCA2 Pathogenic Variants: A Single-Center Retrospective Cohort Study.

    Diaz R, Murelli F, Alessandri F, et al.

    Journal of personalized medicine 2026; (16(6)) doi:10.3390/jpm16060295.

    PMID: 42346606
  13. 13

    Risk-reducing mastectomy for women with hereditary breast and ovarian cancer (HBOC): analytical results of data from the Japanese Organization of HBOC.

    Ohsumi S, Nakamura S, Miyata H, et al.

    Japanese journal of clinical oncology 2022; (52(11)):1265-1269 doi:10.1093/jjco/hyac120.

    PMID: 35905458
  14. 14

    Complications in DIEP Flap Breast Reconstruction After Mastectomy for Breast Cancer: A Prospective Cohort Study Comparing Unilateral Versus Bilateral Reconstructions.

    Wade RG, Razzano S, Sassoon EM, et al.

    Annals of surgical oncology 2017; (24(6)):1465-1474 doi:10.1245/s10434-017-5807-5.

    PMID: 28229288
  15. 15

    Complications Associated with Contralateral Prophylactic Mastectomy: A Systematic Review and Meta-Analysis.

    Murphy AI, Asadourian PA, Mellia JA, Rohde CH

    Plastic and reconstructive surgery 2022; (150()):61S-72S doi:10.1097/PRS.0000000000009493.

    PMID: 35943952
  16. 16

    Mental Health Care among Cancer Patients with BRCA Gene Mutations: The Potential of Mindfulness-based Intervention.

    Takeuchi M, Park S

    The Keio journal of medicine 2025; (74(3)):151-157 doi:10.2302/kjm.2024-0019-RE.

    PMID: 39993778
  17. 17

    [Volume or Value? The Role of the Radiologist in Managing Radiological Exams].

    Silva CF, Guerra T

    Acta medica portuguesa 2017; (30(9)):628-632 doi:10.20344/amp.8253.

    PMID: 29025529
  18. 18

    Impact of radiomics on the breast ultrasound radiologist's clinical practice: From lumpologist to data wrangler.

    Fleury EFC, Marcomini K

    European journal of radiology 2020; (131()):109197 doi:10.1016/j.ejrad.2020.109197.

    PMID: 32795725
  19. 19

    Comprehensive analysis of BRCA1/2 mutations, "BRCAness" and PARP inhibitors in melanoma.

    Stylianakis D, Stylianakis I, Benjamin HA, et al.

    Critical reviews in oncology/hematology 2025; (215()):104962 doi:10.1016/j.critrevonc.2025.104962.

    PMID: 40983306
  20. 20

    Potential New Tumors Associated with Hereditary Breast and Ovarian Cancer (HBOC).

    Nakamura K, Masuda K, Seki T, et al.

    The Keio journal of medicine 2025; (74(3)):158-161 doi:10.2302/kjm.2024-0023-RE.

    PMID: 40074332
  21. 21

    Screening of Patients at Risk for Familial Pancreatic Cancer: What Is Beneficial?

    Torphy RJ, Schulick RD

    The Surgical clinics of North America 2018; (98(1)):25-35 doi:10.1016/j.suc.2017.09.003.

    PMID: 29191275
  22. 22

    [Hereditary gastric and pancreatic cancer].

    Langner C

    Der Pathologe 2017; (38(3)):164-169 doi:10.1007/s00292-017-0297-6.

    PMID: 28484856
  23. 23

    Factors affecting surgical decision-making in carriers of BRCA1/2 pathogenic variants undergoing risk-reducing surgery at a dedicated hereditary ovarian cancer clinic.

    Jacobson MR, Walker M, Ene GEV, et al.

    Menopause (New York, N.Y.) 2021; (29(2)):151-155 doi:10.1097/GME.0000000000001900.

    PMID: 34873108
  24. 24

    Understanding patient priorities: Sexual health and hereditary ovarian cancer syndromes.

    Perez L, Kulkarni A, Lopez S, et al.

    Gynecologic oncology 2026; (205()):113-119 doi:10.1016/j.ygyno.2025.12.010.

    PMID: 41619425
  25. 25

    Can we talk about sex? Feasibility of universal sexual health screening for BRCA1/2 patients.

    Kulkarni A, Perez L, Mitchell L, et al.

    The journal of sexual medicine 2025; (22(11)):2023-2029 doi:10.1093/jsxmed/qdaf256.

    PMID: 41025734

This page explains the role of different medical specialists in managing HBOC syndrome for educational purposes only. Always consult your healthcare provider to build a care team tailored to your specific genetic mutation and health needs.

Get notified when new evidence is published on Hereditary breast and/or ovarian cancer syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.